Excelvision
Warning letter issued January 22, 2026 · Annonay, France
- Inspection
- Jan 12 – Jan 22, 2026
- Investigators
- Justin A. Boyd· Karen A. Briggs· Khoa Nathan V. Tran
- Observations
- 11
- Pages
- 18
- FEI number
- 3007058211
In short: On January 22, 2026, FDA sent a warning letter to Excelvision in Annonay, France (FEI 3007058211). The most-cited regulation is 21 CFR 211.42 (design and construction features).
At a glance
Facilities & equipment and production account for 9 of 11 observations.
Most cited: 21 CFR 211.113(b) (2×)
What the letter cites
Preview: the opening words of each observation- 01
There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch…
- 02
Observation 2: scanned text, readable in the full document.
- 03
Observation 3: scanned text, readable in the full document.
- 04
Observation 4: scanned text, readable in the full document.
7 more observations
Plus the full detail behind each one, exactly as FDA wrote it.
Get the full warning letterThis inspection in context
Justin A. Boyd
61 documents · 2010–2026
Cites 211.113 (control of microbiological contamination) more than any other section. Most of their documents are for sites in India.
The firmExcelvision history
All 6 documents on file for this site, in date order, with what was cited at each inspection.
Similar documentsOther sites cited under 211.113(b)
See how FDA wrote the same problem up elsewhere.
Questions about this warning letter
Who inspected Excelvision?
Justin A. Boyd, Karen A. Briggs and Khoa Nathan V. Tran are named on this Warning letter, for the inspection of Jan 12 – Jan 22, 2026. Each investigator has a profile showing what they cite most.
When was Excelvision inspected by FDA?
The inspection ran Jan 12 – Jan 22, 2026, and the Warning letter is dated January 22, 2026.
How do I get the full Warning letter for Excelvision?
Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.